Digest Réseau Comment ça marche
Réseau
/
Sociétés
Sc
Non vérifié

Scribe Therapeutics, Inc.

Ce que nous écrivons

BiotechnologieCardiologieIndustrieIndustrie pharmaceutiqueSanté

7 communiqués de presse

Voir tous les communiqués de presse
18/06/2026
Marché du travail
Santé
Biotechnologie
Médecine - Divers
Industrie pharmaceutique
Cardiologie
Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials
Source
Scribe Therapeutics, Inc.
Émetteur
Business Wire
1.00
0
28/05/2026
Événements
Industrie
Santé
Biotechnologie
Médecine - Divers
Industrie pharmaceutique
Cardiologie
Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose
Source
Scribe Therapeutics, Inc.
Émetteur
Business Wire
1.00
0
21/05/2026
Industrie
Biotechnologie
Santé
Médecine - Divers
Cardiologie
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
Source
Scribe Therapeutics, Inc.
Émetteur
Business Wire
1.00
0
18/05/2026
Événements
Industrie
Cardiologie
Biotechnologie
Technique
Santé
Industrie pharmaceutique
Science
Logiciels
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
Source
Scribe Therapeutics, Inc.
Émetteur
Business Wire
1.00
0
30/04/2026
Événements
Santé
Biotechnologie
Science
Industrie pharmaceutique
Cardiologie
Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026
Source
Scribe Therapeutics, Inc.
Émetteur
Business Wire
1.00
0
17/02/2026
Industrie
Santé
Biotechnologie
Industrie pharmaceutique
Cardiologie
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
Source
Scribe Therapeutics, Inc.
Émetteur
Business Wire
1.00
0
20/01/2026
Science
Cardiologie
Biotechnologie
Industrie pharmaceutique
Santé
Médecine - Divers
Industrie
Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction
Source
Scribe Therapeutics, Inc.
Émetteur
Business Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0